A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505212-38-00

Acronym

GO43980

Enrollment

Registered

2024-07-02

Start date

2022-11-16

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, Greece, Norway, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026